


Reducing Complication Rates



In a prospective randomized clinical trial of GI cancer surgery patients, those who received IMPACT® formula perioperatively had a 57% lower complication rate vs. control (p=0.02).⁴

Study Objective: To determine if perioperative use of Oral IMPACT®^Δ and IMPACT® immunonutrition (IM) formulas, supplemented with arginine, n-3 fatty acids and nucleotides, were associated with a decrease in postoperative morbidity in malnourished upper and lower GI cancer surgery patients (n=150).

Synopsis:

- Intention to treat analysis showed postoperative complication rates of:
 - **18% with perioperative IM** for 7 days preop, and postop to goal
 - **28% with preoperative IM** for 7 days and postoperative isonitrogenous/isocaloric standard (ST) to goal
 - 42% with control (postoperative ST to goal).
- The most frequent complications were respiratory and wound infections, and anastomotic leak. Trends toward reduction in all were shown in both IM groups.
- **Reduced mean LOS was observed** in perioperative and preoperative IM groups vs. control: 18% and 14%, respectively (p=0.001 and p=0.01).
- Mean LOS between perioperative and preoperative IM groups was also statistically significant (p=0.04).

Outcome Variables	Control Group (n=50)	Preoperative Group (n = 50)	Perioperative Group (n = 50)
Patients with major complications	12	9	6
Patients with infectious complications	12	8	5
Patients with noninfectious complications	11	10	6
Patients with complications, total	21	14	9*
Length of hospital stay, mean (SD), d	15.3 (4.1)	13.2 (3.5) [†]	12.0 (3.8) [‡]

*P = .02 vs the control group.
 †P = .01 vs the control group.
 ‡P < .04 vs the preoperative group and P = .001 vs the control group.

Adapted from Braga et al., Arch. Surg. 2002, Table 6

Complication rate in control group: 42% (=21/50)
 Complication rate in perioperative group: 18% (=9/50)
 Reduction in complication rate: 57%

IMPROVING SURGICAL OUTCOMES WITH

IMPACT® Immunonutrition Formulas

Contains a unique blend of arginine, omega-3 fatty acids (EPA+DHA from fish oil), and nucleotides shown to reduce complications in major elective surgery patients³⁻¹¹

Consistent outcomes in over **80 publications** in major elective surgeries, including:
Upper GI, Lower GI, Cardiac, Head and Neck, Bladder Cancer, Gyn-Oncology, Hip



Nutrition Information

Serving Size	IMPACT ADVANCED RECOVERY® Drink		IMPACT® Formula	IMPACT® Peptide 1.5 Formula
	Per 178 mL carton	Per 534 mL (3 cartons)	Per 1000 mL	Per 1000 mL
Supplemental L-arginine (g)	4.2	12.6	12.5	18.7
EPA + DHA (g)	1.1	3.3	1.7	4.9
Nucleotides (g)	0.43	1.3	1.2	1.8
Calories (kcal)	200	600	1,000	1,500
Protein (g)	18 (35% of total kcal)	54 (35% of total kcal)	56 (22% of total kcal)	94 (25% of total kcal)

Ordering Information

PRODUCT	PRODUCT CODE	NDC FORMAT NUMBER	CASE UPC (GTIN)	PACKAGING
IMPACT® Unflavored	35810000	43900-0358-10	10043900358106	24-250 mL cartons/case
IMPACT® UltraPak® System	35810800	43900-0358-18	10043900358182	6-1000 mL bags/case
IMPACT ADVANCED RECOVERY® Vanilla	4390099291	43900-0992-90	00043900992914	15-178 mL cartons/case
IMPACT® Peptide 1.5 Unflavored	4390097400	43900-0973-99	10043900974009	24-250 mL cartons/case
IMPACT® Peptide 1.5 UltraPak® System	4390097371	43900-0973-70	10043900973712	6-1000 mL bags/case

NDC Formatted Numbers are not actual National Drug Codes (NDC). They are product codes adjusted according to standard industry practice to meet the format requirements of certain suppliers and payers. Nestlé HealthCare Nutrition submits product information including various product codes to the compendia including First Data Bank, RedBook and Medispan but cannot confirm that the NDC Formatted Numbers submitted have been published by the compendia.

References 1. Mauskopf JA et al. *WJSO* 2012;10:136. 2. Braga M et al. *Nutrition* 2005;21:1078-1086. 3. Braga M et al. *Surgery* 2002;132(5):805-814. 4. Braga M et al. *Arch Surg* 2002;137:174-180. 5. Drover JW et al. *J Am Coll Surg* 2011;212(3):385-399. 6. Ferreras N et al. *Clin Nutr* 2005;24:55-65. 7. Rowan NR et al. *Oral Onc* 2016;54:42-46. 8. Waitzberg DL et al. *World J Surg* 2006;30:1592-1604. 9. Chapman JS et al. *Gynecologic Oncology* 2015;137:523-528. 10. Tepaske R et al. *JPEN* 2007;31(3):173-180. 11. Bertrand J et al. *World J Urol* 2014;32:233-237.

USE UNDER MEDICAL SUPERVISION. NOT INDICATED WHEN IMMUNE SUPPRESSION IS DESIRED.

www.NestleHealthScience.us • 1-800-422-ASK2 (2752)

All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland.
©2016 Nestlé. All rights reserved.

IPCT-12015-0119

